Dravet and Lennox-Gastaut Syndromes research hub

A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

This study looks at the long-term safety and how well a medicine called soticlestat works for people with Dravet Syndrome or Lennox-Gastaut Syndrome. It's for those already in a previous study and focuses on side effects and overall health.